trending Market Intelligence /marketintelligence/en/news-insights/trending/mxopqtu8ietb9zj9cgqtaq2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

ANI Pharmaceuticals launches authorized generic of bipolar drug

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry

Cable Nets Struggle With Little Revenue Growth Expanding Programming Budgets


ANI Pharmaceuticals launches authorized generic of bipolar drug

ANI Pharmaceuticals Inc. launched an authorized generic of its bipolar drug Lithobid.

The lithium carbonate tablets will be available in 300 mg doses and will compete with existing generics in the market. IMS Health estimates that the U.S. market for lithium carbonate is about $19 million.